CD70 definition

CD70 means the protein encoded by the CD70 (Cluster of Differentiation 70, Entrez Gene: 970) gene which is known to be a cytokine in the tumor necrosis factor (TNF) ligand family.
View Source

Examples of CD70 in a sentence

  • Cusatuzumab is an investigational therapeutic antibody that targets CD70, an immune checkpoint implicated in numerous cancers, including hematological malignancies.

  • The data showed promising anti-leukemia activity in these patients.i “We believe CD70 is an important target in the biology of select cancers, and we are eager to accelerate the development of this innovative antibody together with argenx,” said ▇▇▇▇▇ ▇▇▇▇▇▇▇, M.D., MHSc, Ph.D., Vice President, Hematologic Malignancies Disease Area Leader, ▇▇▇▇▇▇▇ Research & Development, LLC.

  • Cusatuzumab is designed to: block CD70; kill cancer cells expressing CD70 through complement-dependent cytotoxicity, enhanced antibody-dependent cell-mediated phagocytosis and enhanced antibody-dependent cell-mediated cytotoxicity; and restore immune surveillance against solid tumors.

  • In this regard one of the options being propagated by the non-proliferation community is to have a regional fissile material control arrangement involving China, India and Pakistan pending formal negotiations at the Conference on Disarmament (CD).70 It however would remain a debatable preposition as China would not like itself to be equated with South Asian neighbors in terms of its nuclear capability, while US remains outside of any obligations.

  • Cusatuzumab (ARGX-110) is an investigational SIMPLE Antibody™ targeting CD70, an immune checkpoint target involved in hematological malignancies, several solid tumors and severe autoimmune diseases.

  • Under the agreement, the companies will co-develop and co-commercialize two CAR NK cell product candidates, one targeting the CD70 tumor antigen and the other target to be determined.

  • CRISPR’s deep understanding of CD70 biology and experience in allogeneic T cell clinical development can accelerate the development of early-stage Nkarta programs, to deliver innovative treatments to patients that much faster.” Nkarta management will host a conference call to discuss the collaboration today at 4:30 p.m. Eastern Time (ET).

  • Beyond efgartigimod, we continue to co-develop our second lead product candidate, cusatuzumab (, or ARGX- 110), (targeting CD70) with our collaborator, Cilag GmbH International, an affiliate of the ▇▇▇▇▇▇▇ Pharmaceutui- calPharmaceutical Companies of ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇, or Cilag, for the rare and aggressive hematological cancer acute myeloid leukemia, or AML, as well as high-risk myelodysplastic syndrome, or MDS.

  • As a result, we have entered into collaborations with a number of biopharmaceutical companies, including our collaboration with ▇▇▇▇▇▇▇ for cusatuzumab, our product candidate targeting CD70 for rare and aggressive hematological cancers and with AbbVie for ARGX-115 (ABBV-151), a cancer immunotherapy-focused product candidate against the novel target GARP.

  • Beyond efgartigimod, we continue to co-develop our second lead product candidate, cusatuzumab (, or ARGX- 110), (targeting CD70) with our collaborator, Cilag GmbH International, an affiliate of the ▇▇▇▇▇▇▇ PharmaceutuicalPharmaceutical Companies of ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇, or Cilag, for the rare and aggressive hematological cancer acute myeloid leukemia, or AML, as well as high-risk myelodysplastic syndrome, or MDS.